Improving outcome in schizophrenia: The case for early intervention

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 6, 1999, Pages 843-846

  Malla, Ashok K ^a,b   Norman, Ross M G ^b   Voruganti, L Panth ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AFFECT; BEHAVIOR; DELUSION; FOLLOW UP; HALLUCINATION; HOSPITAL ADMISSION; HUMAN; PROGNOSIS; SCHIZOPHRENIA; SHORT SURVEY; SOCIAL BEHAVIOR; SYMPTOM; TREATMENT OUTCOME;

EID: 0033596893     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (74)

1. 1. Where next with psychiatric illness? Nature 1988;36(10):95-6.
2. 2. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: Wat could have been prevented? Acta Psychiatr Scand 1990;81:231-5.
3. 3. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980;6:592-605.
4. 4. McGlashan TH. The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 1984;41:586-601.
5. 5. Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull 1988;14:633-43.
6. 6. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 1980;6:606-18.
7. 7. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997;42:34-43.
8. 8. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988;14:515-42.
9. 9. Carone BJ, Harrow M, Westermeyer JF. Posthospital course and outcome in schizophrenia. Arch Gen Psychiatry 1991;48:247-53.
10. 10. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.
11. 11. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
12. 12. Marder SR, May PR. Benefits and limitations of neuroleptics - and other forms of treatment - in schizophrenia. Am J Psychother 1986;40:357-69.
13. 13. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-51.
14. 14. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
15. 15. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;Suppl 17:46-53.
16. 16. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfeit A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
17. 17. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
18. 18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
19. 19. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. The Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
20. 20. Small JG, Hirsch SR, Arvanitis LA, Miller GB, Link CG. Quetlapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
21. 21. Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA. ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 1996;168(Suppl 2):45-56.
22. 22. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
23. 23. Green MG, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
24. 24. Green MG. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry 1996;153:321-30.
25. 25. Norman R, Malla A, Cortese L, Cheng S, Diaz K, McIntosh E, et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am J Psychiatry. In press.
26. 26. deJesus MJ, Steiner DL. An overview of family intervention and relapse on schizophrenia: a meta-analysis of research findings. Psychol Med 1994;24:565-78.
27. 27. Benton MK, Schroeder HE. Social skills training with schizophrenics: a meta-analytic evaluation. J Consult Clin Psychol 1990;58:741-7.
28. 28. Bell MD, Lysaker PH, Milstein RM. Clinical benefits of paid work activity in schizophrenia. Schizophr Bull 1996;22:51-67.
29. 29. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald D, Ulrich RF, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia II. Two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991;48:340-7.
30. 30. Goering PN, Farkas M, Wasylenki DA, Lancee WJ, Ballantyne R. Improved functioning for case management clients. Psychosoc Rehabil J 1988;12:3-17.
31. 31. Stein LI, Test MA. Alternative to mental hospital treatment: I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980;37:392-7.
32. 32. Holloway F, Carson J. Intensive case management for the severely mentally ill. Controlled trial, Br J Psychiatry 1998;172:19-22.
33. 33. Carpenter WT Jr, Strauss JS. The prediction of outcome in schizophrenia. IV: Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 1991;179:517-25.
34. 34. Mason P, Harrison G, Glazebrook C, Medley I, Dalkin T, Croudace T. Characteristics of outcome in schizophrenia at 13 years. Br J Psychiatry 1995;167:596-603.
35. 35. Verghese A, John JK, Rajkumar S, Richard J, Sethi BB, Trivedi JK. Factors associated with the course and outcome of schizophrenia in India. Results of a two-year multicentre follow-up study. Br J Psychiatry 1989;154:499-503.
36. 36. Leon CA. Clinical course and outcome of schizophrenia in Cali, Colombia: a 10-year follow-up study. J New Ment Dis 1989;177:593-606.
37. 37. Left J, Satorius N, Jablensky A, Korten A, Emberg G. The International Pilot Study of Schizophrenia: five year follow-up findings. Pychol Med 1992;22:131-45.
38. 38. Thara R, Henrietta M, Joseph A, Rajkumar S, Eaton WW. Ten-year course of schizophrenia - the Madras longitudinal study. Acta Psychiatr Scand 1994; 90:329-36.
39. 39. Bachrach LL. Assessment of outcomes in community support systems: results, problems, and limitations. Schizophr Bull 1982;8:39-61.
40. 40. Brekke JS. What do we really know about community support programs? Strategies for better monitoring. Hosp Community Psychiatry 1988;39(9):946-52.
41. 41. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry 1996;153:607-17.
42. 42. Thornicroft G, Wykes T, Holloway F, Johnson S, Szmukler G. From efficacy to effectiveness in community mental health services. Br J Psychiatry 1998; 173:423-427.
43. 43. Seeman MV, Lang M. The role of oestrogens in schizophrenia: gender differences. Schizophr Bull 1990;16:185-94.
44. 44. Salokanagas RKR. Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 1983;142:145-51.
45. 45. Angermeyer MC, Kuhn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 1990;16:293-307.
46. 46. World Health Organization. Shizophrenia: an international follow-up study. Geneva: Wiley; 1979.
47. 47. Kavanagh DJ. Recent developments in expressed emotion and schizophrenia. Br J Psychiatry 1992;160:601-20.
48. 48. Lieberman JA, Jody D, Geisler SH, Alvir JMJ, Loebel AD, Symanski SR, et al. Time course and biological correlates of treatment response to first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76.
49. 49. Lysaker PH, Bell M, Bioty SM. Cognitive deficits in schizophrenia. Prediction of symptom change for participators in work rehabilitation. J Nerv Ment Dis 1995;183:332-6.
50. 50. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzen LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20:145-51.
51. 51. Strauss JS, Carpenter WT Jr. Prediction of outcome in schizophrenia: III. Five-year outcome and its predictors. Arch Gen Psychiatry 1977;34:159-63.
52. 52. Kendler KS, Gruenberg AM, Tsuang MT. Outcome of schizophrenic subtypes defined by four diagnostic systems. Arch Gen Psychiatry 1984;41:149-54.
53. 53. Peterson DB, Olson GW. First admitted schizophrenics in drug era. Arch Gen Psychiatry 1964;11:137-44.
54. 54. Waddington JL, Youssef HA, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995;25:849-57.
55. 55. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-7.
56. 56. Johnstone EC, Frith CD, Crow TJ, Owens DGC, Done DJ, Baldwin EJ, et al. The Northwick Park 'Functional' Psychosis Study: diagnosis and outcome. Psychol Med 1992;22:331-46.
57. 57. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149(9):1183-8.
58. 58. Kane J. The current status of neuroleptics. J Clin Psychiatry 1989;50:322-8.
59. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
60. 60. Beels C. Social support and schizophrenia. Schizophr Bull 1981;7:58-72.
61. 61. Jorgensen P. Recovery and insight in schizophrenia. Acta Psychiatr Scand 1995;92(6):436-40.
62. 62. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996;22:241-56.
63. 63. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22:305-26.
64. 64. McGorry PD. Early psychosis prevention and intervention centre. Australas Psychiatry 1993;1:32-4.
65. 65. Edwards J, Francey SM, McGorry PD, Jackson HJ. Early psychosis prevention and intervention: evolution of a comprehensive community-based specialized service. Behav Change 1994;11(4):223-33.
66. 66. McGlashan TIL Early detection and intervention in schizophrenia: research. Schizophr Bull 1996;22:327-45.
67. 67. Malla AK, Norman RMG. Prodromal symptoms in schizophrenia. Br J Psychiatry 1994;164:487-93.
68. 68. Norman RMG, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull 1995;21:527-39.
69. 69. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-70.
70. 70. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GE, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996;22:283-303.
71. 71. Gordan R. An operation classification of disease prevention. Public Health Rep 1983;98:107-9.
72. 72. Mrazek JP, Hegarry RJ. Reducing risk for mental disorders: frontiers for preventive intervention research. Washington: National Academy Press; 1994. p. 25.
73. 73. Falloon IRH, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996;22:271-82.
74. 74. Falloon IRH. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992;55:4-15.